Glycolysis gatekeeper PDK1 was an essential regulator of gefitinib resistance in lung cancer. (IMAGE)
Caption
: (A) The PC-9 and PC-9/G cells were treated with various concentrations of gefitinib for 72 h, and cell viabilities were detected by CCK-8 assay. (B) PC-9/G cells induced higher glucose consumption and lactate production rates compared with PC-9 cells. (C) The mRNA and protein expression levels of PDK1 were tested by quantitative reverse transcription PCR and Western blotting in PC-9 and PC-9/G cell lines. (D) The protein expression levels of PDK1 were tested by Western blotting in PC-9, PC-9/OR, HCC827, and HCC827/OR cell lines. (E) Indicated cells were treated with gefitinib of different concentrations for 72 h, and PDK1 knockdown in PC-9/G cells rendered cells more sensitive to gefitinib, while forced expression of PDK1 in PC-9 cells made cells more resistant to gefitinib. (F) The apoptosis rates were determined by flow cytometry, and PDK1 knockdown in PC-9/G cells induced higher apoptosis rates. Data were statistically analyzed with Student’s t-test, and values were shown as mean ± standard deviation. ∗P < 0.05 and ∗∗P < 0.01.
Credit
Zhihao Zhou, Ruike Zhang, Zhaoyang Zhang, Liyuan Zhang, Wei Wang, Wenjing Liu, Chunyang Zhang, Gen Lin, Weimiao Yu, Bo Xu, Lin Wang, Bing-Hua Jiang
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND